Legend Biotech Corporation (LEGN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Is Legend Biotech Corporation stock overvalued or undervalued in 2026?
As of October 30, 2026, Legend Biotech Corporation (LEGN) trades at $21.63 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Legend Biotech Corporation
Market cap $4B · 52 weeks $17 – $36 (40 % below the high) · P/E no earnings · 2027 expected P/E 40.0× · Dividend none · Next earnings November 10, 2026 · expected EPS $0.01 · Closing price, Oct 30 · accounts published Aug 11.
- Valuation: P/Sales 3.8× (no earnings).
- Balance sheet: Grey zone (watch).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 3 of 4 pass
- Market cap / Cash 4.2×, fails.
- Cash Runway 113 meses, passes.
- Total Debt 0.5×, passes.
- R&D / Market cap 10.4 %, passes, near the threshold.
- Annual cash burn $0.55, info.
Against its peers (reference peers) — Legend Biotech Corporation: P/E —; EV/EBITDA —; ROIC -3.7 %; $4.0B. Arcutis Biotherapeutics, Inc. (P/E 154×; EV/EBITDA 94.7×; ROIC 9.9 %; $4.0B), Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 30.4×; ROIC 4.9 %; $5.0B).
Profitability
| Return on Equity | -8.70% |
| Return on Invested Capital | -3.71% |
| Return on Assets | -5.23% |
| Gross Margin | 56.58% |
| Operating Margin | -4.42% |
| Net Margin | -7.21% |
Financial Health
| Debt / Equity | 0.23 |
| Current Ratio | 3.04 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.46 |
Price Performance
| 1 month | +16.48% |
| 3 months | +13.78% |
| Year-to-date | -0.51% |
| 1 year | -33.24% |
| 3 years | -66.61% |
| 5 years | -58.71% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of LEGN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks